---
document_datetime: 2025-11-23 07:00:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/viekirax.html
document_name: viekirax.html
version: success
processing_time: 0.1364717
conversion_datetime: 2025-12-29 22:21:34.5459
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Viekirax

[RSS](/en/individual-human-medicine.xml/67000)

##### Withdrawn

This medicine's authorisation has been withdrawn

ombitasvir / paritaprevir / ritonavir Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Viekirax](#news-on)
- [More information on Viekirax](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 25 September 2024, the European Commission withdrew the marketing authorisation for Viekirax (ombitasvir / paritaprevir / ritonavir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AbbVie Deutschland GmbH &amp; Co. KG, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Viekirax was granted marketing authorisation in the EU on 15 January 2015 for treatment of chronic hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2019. The European Public Assessment Report (EPAR) for Viekirax is updated to indicate that the marketing authorisation is no longer valid.

Viekirax : EPAR - Medicine overview

Reference Number: EMA/733678/2014

English (EN) (173.05 KB - PDF)

**First published:** 09/03/2015

**Last updated:** 02/10/2024

[View](/en/documents/overview/viekirax-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-449)

български (BG) (233.95 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/bg/documents/overview/viekirax-epar-medicine-overview_bg.pdf)

español (ES) (170.46 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/es/documents/overview/viekirax-epar-medicine-overview_es.pdf)

čeština (CS) (215.75 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/cs/documents/overview/viekirax-epar-medicine-overview_cs.pdf)

dansk (DA) (169.12 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/da/documents/overview/viekirax-epar-medicine-overview_da.pdf)

Deutsch (DE) (178.27 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/de/documents/overview/viekirax-epar-medicine-overview_de.pdf)

eesti keel (ET) (158.8 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/et/documents/overview/viekirax-epar-medicine-overview_et.pdf)

ελληνικά (EL) (255.38 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/el/documents/overview/viekirax-epar-medicine-overview_el.pdf)

français (FR) (173.13 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/fr/documents/overview/viekirax-epar-medicine-overview_fr.pdf)

hrvatski (HR) (205.8 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/hr/documents/overview/viekirax-epar-medicine-overview_hr.pdf)

italiano (IT) (166.34 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/it/documents/overview/viekirax-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (220.9 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/lv/documents/overview/viekirax-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (210.43 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/lt/documents/overview/viekirax-epar-medicine-overview_lt.pdf)

magyar (HU) (202.26 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/hu/documents/overview/viekirax-epar-medicine-overview_hu.pdf)

Malti (MT) (216.22 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/mt/documents/overview/viekirax-epar-medicine-overview_mt.pdf)

Nederlands (NL) (173.75 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/nl/documents/overview/viekirax-epar-medicine-overview_nl.pdf)

polski (PL) (211.32 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/pl/documents/overview/viekirax-epar-medicine-overview_pl.pdf)

português (PT) (172.62 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/pt/documents/overview/viekirax-epar-medicine-overview_pt.pdf)

română (RO) (216.56 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/ro/documents/overview/viekirax-epar-medicine-overview_ro.pdf)

slovenčina (SK) (207.36 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/sk/documents/overview/viekirax-epar-medicine-overview_sk.pdf)

slovenščina (SL) (197.94 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/sl/documents/overview/viekirax-epar-medicine-overview_sl.pdf)

Suomi (FI) (165.72 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/fi/documents/overview/viekirax-epar-medicine-overview_fi.pdf)

svenska (SV) (169.98 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/sv/documents/overview/viekirax-epar-medicine-overview_sv.pdf)

Viekirax : EPAR - Risk-management-plan summary

English (EN) (272.98 KB - PDF)

**First published:** 09/03/2015

**Last updated:** 02/10/2024

[View](/en/documents/rmp-summary/viekirax-epar-risk-management-plan-summary_en.pdf)

## Product information

Viekirax : EPAR - Product Information

English (EN) (2.59 MB - PDF)

**First published:** 09/03/2015

**Last updated:** 02/10/2024

[View](/en/documents/product-information/viekirax-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-482)

български (BG) (2.74 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/bg/documents/product-information/viekirax-epar-product-information_bg.pdf)

español (ES) (2.84 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/es/documents/product-information/viekirax-epar-product-information_es.pdf)

čeština (CS) (2.69 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/cs/documents/product-information/viekirax-epar-product-information_cs.pdf)

dansk (DA) (2.67 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/da/documents/product-information/viekirax-epar-product-information_da.pdf)

Deutsch (DE) (2.81 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/de/documents/product-information/viekirax-epar-product-information_de.pdf)

eesti keel (ET) (2.46 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/et/documents/product-information/viekirax-epar-product-information_et.pdf)

ελληνικά (EL) (2.98 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/el/documents/product-information/viekirax-epar-product-information_el.pdf)

français (FR) (2.63 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/fr/documents/product-information/viekirax-epar-product-information_fr.pdf)

hrvatski (HR) (2.6 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/hr/documents/product-information/viekirax-epar-product-information_hr.pdf)

íslenska (IS) (2.66 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/is/documents/product-information/viekirax-epar-product-information_is.pdf)

italiano (IT) (2.85 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/it/documents/product-information/viekirax-epar-product-information_it.pdf)

latviešu valoda (LV) (2.73 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/lv/documents/product-information/viekirax-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.74 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/lt/documents/product-information/viekirax-epar-product-information_lt.pdf)

magyar (HU) (2.6 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/hu/documents/product-information/viekirax-epar-product-information_hu.pdf)

Malti (MT) (2.87 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/mt/documents/product-information/viekirax-epar-product-information_mt.pdf)

Nederlands (NL) (2.55 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/nl/documents/product-information/viekirax-epar-product-information_nl.pdf)

norsk (NO) (2.69 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/no/documents/product-information/viekirax-epar-product-information_no.pdf)

polski (PL) (2.8 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/pl/documents/product-information/viekirax-epar-product-information_pl.pdf)

português (PT) (2.28 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/pt/documents/product-information/viekirax-epar-product-information_pt.pdf)

română (RO) (2.85 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/ro/documents/product-information/viekirax-epar-product-information_ro.pdf)

slovenčina (SK) (2.81 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/sk/documents/product-information/viekirax-epar-product-information_sk.pdf)

slovenščina (SL) (2.67 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/sl/documents/product-information/viekirax-epar-product-information_sl.pdf)

Suomi (FI) (2.75 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/fi/documents/product-information/viekirax-epar-product-information_fi.pdf)

svenska (SV) (2.64 MB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/sv/documents/product-information/viekirax-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** EMEA/H/C/WS/2430 12/08/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Viekirax : EPAR - All Authorised presentations

English (EN) (41.14 KB - PDF)

**First published:** 09/03/2015

**Last updated:** 02/10/2024

[View](/en/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-659)

български (BG) (64.42 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/bg/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.93 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/es/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_es.pdf)

čeština (CS) (55.26 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/cs/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (41.92 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/da/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.36 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/de/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (43.11 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/et/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (63.65 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/el/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_el.pdf)

français (FR) (42.22 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/fr/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (49.03 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/hr/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (37.98 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/is/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_is.pdf)

italiano (IT) (41.88 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/it/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (59.67 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/lv/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (61.54 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/lt/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (47.21 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/hu/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (53.1 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/mt/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (41.86 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/nl/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (37.91 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/no/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_no.pdf)

polski (PL) (48.36 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/pl/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_pl.pdf)

português (PT) (42.61 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/pt/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_pt.pdf)

română (RO) (55.08 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/ro/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (50.09 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/sk/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (54.26 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/sl/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (41.9 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/fi/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (37.49 KB - PDF)

**First published:**

09/03/2015

**Last updated:**

02/10/2024

[View](/sv/documents/all-authorised-presentations/viekirax-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Viekirax Active substance

- ombitasvir
- paritaprevir
- ritonavir

International non-proprietary name (INN) or common name

- ombitasvir
- paritaprevir
- ritonavir

Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AP53

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.

For hepatitis C virus (HCV) genotype specific activity.

## Authorisation details

EMA product number EMEA/H/C/003839 Marketing authorisation holder

AbbVie Deutschland GmbH &amp; Co. KG

Knollstrasse 67061 Ludwigshafen Germany

Opinion adopted 20/11/2014 Marketing authorisation issued 14/01/2015 Withdrawal of marketing authorisation 25/09/2024 Revision 28

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Viekirax : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.5 MB - PDF)

**First published:** 28/09/2015

**Last updated:** 02/10/2024

[View](/en/documents/procedural-steps-after/viekirax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Viekirax-H-C-PSUV/SA/Art 20/Art 107i/Art 3 : Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (136.16 KB - PDF)

**First published:** 07/07/2022

**Last updated:** 02/10/2024

[View](/en/documents/scientific-conclusion/viekirax-h-c-psuv-sa-art-20-art-107i-art-3-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Viekirax-H-C-3839-P46-023 : EPAR - Assessment report

Adopted

Reference Number: EMA/92477/2021

English (EN) (544.96 KB - PDF)

**First published:** 01/09/2021

**Last updated:** 02/10/2024

[View](/en/documents/variation-report/viekirax-h-c-3839-p46-023-epar-assessment-report_en.pdf)

Viekirax-H-C-3839-P46-0021 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/105448/2019

English (EN) (1.94 MB - PDF)

**First published:** 30/08/2021

**Last updated:** 02/10/2024

[View](/en/documents/variation-report/viekirax-h-c-3839-p46-0021-epar-assessment-report_en.pdf)

Viekirax-H-C-PSUSA-10367-201801 : Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/633999/2018

English (EN) (117.01 KB - PDF)

**First published:** 11/12/2018

**Last updated:** 02/10/2024

[View](/en/documents/scientific-conclusion/viekirax-h-c-psusa-10367-201801-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Viekirax (WS-1348)

Adopted

Reference Number: EMA/CHMP/500340/2018

English (EN) (154.42 KB - PDF)

**First published:** 27/07/2018

**Last updated:** 02/10/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viekirax-ws-1348_en.pdf)

Viekirax-H-C-3839-A20-0018 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/103226/2017

English (EN) (1.19 MB - PDF)

**First published:** 13/03/2017

**Last updated:** 02/10/2024

[View](/en/documents/variation-report/viekirax-h-c-3839-a20-0018-epar-assessment-report-variation_en.pdf)

Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion

English (EN) (219.64 KB - PDF)

**First published:** 13/03/2017

**Last updated:** 02/10/2024

[View](/en/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_en.pdf)

[Other languages (22)](#file-language-dropdown-589)

български (BG) (340.62 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/bg/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_bg.pdf)

español (ES) (216.72 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/es/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_es.pdf)

čeština (CS) (282.49 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/cs/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_cs.pdf)

dansk (DA) (225.38 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/da/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (246.2 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/de/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (214.88 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/et/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (375.22 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/el/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_el.pdf)

français (FR) (219.59 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/fr/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_fr.pdf)

hrvatski (HR) (295.32 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/hr/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_hr.pdf)

italiano (IT) (232.47 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/it/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (334.56 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/lv/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (299.54 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/lt/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_lt.pdf)

magyar (HU) (247.73 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/hu/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_hu.pdf)

Malti (MT) (315.95 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/mt/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_mt.pdf)

Nederlands (NL) (236.87 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/nl/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_nl.pdf)

polski (PL) (288.39 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/pl/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_pl.pdf)

português (PT) (221.47 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/pt/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_pt.pdf)

română (RO) (304.34 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/ro/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_ro.pdf)

slovenčina (SK) (269.89 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/sk/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (306.08 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/sl/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (221.13 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/fi/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_fi.pdf)

svenska (SV) (222.65 KB - PDF)

**First published:**

13/03/2017

**Last updated:**

02/10/2024

[View](/sv/documents/scientific-conclusion/viekirax-h-c-3839-a20-0018-epar-scientific-conclusion_sv.pdf)

Viekirax-H-C-PSUSA-00010367-201507 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/268539/2016

English (EN) (109.93 KB - PDF)

**First published:** 25/05/2016

**Last updated:** 02/10/2024

[View](/en/documents/scientific-conclusion/viekirax-h-c-psusa-00010367-201507-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Viekirax : EPAR - Public assessment report

Adopted

Reference Number: EMA/768346/2014

English (EN) (7.76 MB - PDF)

**First published:** 09/03/2015

**Last updated:** 02/10/2024

[View](/en/documents/assessment-report/viekirax-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Viekirax

Adopted

Reference Number: EMA/CHMP/688255/2014

English (EN) (139.1 KB - PDF)

**First published:** 21/11/2014

**Last updated:** 02/10/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-viekirax_en.pdf)

#### News on Viekirax

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

[Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B](/en/news/direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b) 16/12/2016

[PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C](/en/news/prac-warns-risk-hepatitis-b-re-activation-direct-acting-antivirals-hepatitis-c) 02/12/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-november-2014) 21/11/2014

[Two new medicines recommended for the treatment of chronic hepatitis C](/en/news/two-new-medicines-recommended-treatment-chronic-hepatitis-c) 21/11/2014

#### More information on Viekirax

- [EMEA-001440-PIP01-13-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001440-pip01-13-m03)
- [Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free) - referral](/en/medicines/human/referrals/direct-acting-antivirals-indicated-treatment-hepatitis-c-interferon-free)
- [A study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (De Novo DAA PASS) - post-authorisation study](https://catalogues.ema.europa.eu/study/44706)

**This page was last updated on** 02/10/2024

## Share this page

[Back to top](#main-content)